Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Mitoxantrone Can Extend Time to Disease Progression in Worsening Multiple Sclerosis: Presented at AAN By Maria Bishop BOSTON, MA -- May 7, 2007 -- The results of the Registry to Evaluate Novantrone Effects in Worsening MS (RENEW) study continue to demonstrate the benefits of using immunosuppression with mitoxantrone in patients with multiple sclerosis (MS). Researchers presented the study findings here at the American Academy of Neurology (AAN) 59th Annual Meeting. A total of 509 patients receiving mitoxantrone for the treatment of worsening relapsing-remitting MS (WRRMS), progressive-relapsing MS (PRMS), or secondary-progressive MS (SPMS) were enrolled at 46 centers across the United States from April 2001 through January 15, 2007. A total of 327 relapses were reported in 241 patients, with the median time to first relapse being 158 days (range, 3 days to 1,215 days), according to lead investigator Victor Rivera, MD, medical director, Maxine Mesinger MS Clinic, Baylor College of Medicine Multiple Sclerosis Center, Houston, Texas. Previous research has shown that early and aggressive treatment with mitoxantrone may delay or limit long-term disability. Of the 509 patients enrolled into the RENEW study, 62 continue on mitoxantrone treatment. The majority of reasons given for stopping the study treatment included physician decision (31%) and patient request (27%). The authors noted that, in a population representing 736.9 patient years on mitoxantrone, the results of the RENEW study to date continue to support the use of mitoxantrone. Follow-up data continue to be collected for 224 of the 447 patients who stopped treatment, with the intention of extending long-term safety and tolerability data. It is well known that the risk of cardiotoxicity with mitoxantrone treatment increases with cumulative doses; the package insert urges that cardiac function be monitored on a regular basis before every dose, the researchers noted. This study was supported by EMD Serono. [Presentation title: Ongoing Evaluation of the Safety and Tolerability of Mitoxantrone in Worsening Multiple Sclerosis: The RENEW Study. Abstract P06.080] E-mail this page to a friend or colleague! To print, use this version